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ERA = endothelin receptor antagonist; NF = nuclear factor; PAH = pulmonary arterial hypertension; PDE = phosphodiesterase; RP = Raynaud’s
phenomenon; SScl = systemic sclerosis.
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Vasculopathy is an increasingly recognised partner to
inflammatory rheumatological disease. Raynaud’s phenomenon
(RP) is generally considered a benign vascular manifestation.
The natural history of systemic sclerosis (SScl), however,
suggests that we underestimate the significance of RP in this
context. RP occurs in approximately 90% of SScl patients,
often decades before the diagnosis is recognised, and is a
harbinger of generalised vasculopathy. Pulmonary arterial
hypertension (PAH) is another manifestation of this process,
which occurs in approximately 12% of SScl patients [1]. PAH
accounts for approximately 50% of mortality in limited SScl
and accounts for approximately 7% of mortality in diffuse
SScl. It is probable that the vasculopathic processes
underlying RP and PAH contribute to the familiar pattern of
skin, renal and gastrointestinal pathology. The emergence of
effective and conveniently administered therapy for PAH
increases the importance of diagnosis and monitoring of this
complication. Furthermore, since many principles of PAH
management translate to the management of RP, this raises
the possibility that the generalised vasculopathy of SScl may
also be modifiable.
In the characteristic microangiopathy of SScl, luminal
narrowing results from a combination of intimal proliferation,
medial hypertrophy and adventitial fibrosis [2]. This leads to a
state of progressive chronic organ ischaemia. Dysfunction of
cellular components of the arterial wall and dysfunction of
inflammatory and haemostatic systems are interrelated
(Fig. 1) [3,4]. Endothelial cell dysfunction is characterised by
decreased production of the vasodilators nitric oxide and
prostacyclin, and by enhanced release of endothelin-1.
Endothelial cell dysfunction influences the behaviour of
vascular smooth muscle cells and adventitial fibroblasts,
which mediate the proliferative changes and sclerosis in the
sclerodermatous arterial wall. An appreciation of the cross-
talk between these arterial wall components underlies the
therapeutic paradigm shift from the use of pure vasodilators
to agents with antiproliferative activity [5]. Endothelin receptor
antagonists (ERA) are in the vanguard of these new manage-
ment strategies. Phosphodiesterase (PDE) type V inhibitors,
angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers are also promising.
Endothelin-1 causes vasoconstriction and vascular smooth
muscle cell proliferation, promotion of inflammation and
fibrosis [5,6]. Two double-blind, placebo-controlled trials of
an oral ERA, bosentan, were published in 2001 and 2002.
These reported significant improvement in pulmonary haemo-
dynamics and exercise capacity (P < 0.001) in patients with
both primary and SScl-associated PAH, following a treatment
period of 12–16 weeks [7,8]. Subgroup analysis suggested
that the prognosis of PAH in SScl was worse than the
prognosis of primary PAH but that the relative benefit of
bosentan was similar in both contexts. Although bosentan
was generally well tolerated, it was associated with a dose-
dependent increase in hepatic aminotransferases, which
resolved on withdrawal of the drug. Although encouraging,
these studies could not predict whether benefit would be
maintained long term or, indeed, whether the apparent
efficacy would translate into decreased mortality.
An extension study from the two trials combined collates data
from 169 patients with severe (World Health Organisation
Functional Class III or Class IV) primary PAH, who received
bosentan as first-line therapy (i.e. no prior exposure to
prostanoids) for up to 3 years [9]. Survival was calculated,
according to baseline haemodynamic status, using a formula
based on data from 187 primary PAH patients in the National
Institutes of Health Registry, and was compared with
predicted survival. The study indicates that bosentan
substantially increases survival, with survival estimates at
1 year and 2 years of 96% and 89% compared with
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predicted survivals of 69% and 57%, respectively. Although
abnormal liver function tests occurred in approximately 15%
of the patients, no serious hepatic sequelae were
documented in this group. Since the prognosis of PAH is
generally worse in SScl, survival is likely to be lower in this
group, but the data from short-term studies suggest that a
similar relative benefit of bosentan may be anticipated [7,8].
Data demonstrating the efficacy of ERAs in SScl-associated
PAH and in patients in World Health Organisation Functional
Class II are awaited. The combined vasodilator/antiproliferative/
antifibrotic activity of ERAs raises the exciting prospect for
management of peripheral vasculopathy in SScl. Last year,
the RAPIDS-1 study reported that bosentan approximately
halved the incidence of new digital ulcers in patients with a
history of digital ulceration [10]. The RAPIDS-2 study,
designed specifically to assess the effect of bosentan on
ulcer healing, is expected to report later this year.
Other medications that may combine vasodilator and anti-
proliferative activity include angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers and PDE type V
inhibitors [5]. The use of angiotensin-converting enzyme
inhibitors in SScl to prevent scleroderma renal crisis is well
established [11]. Studies in animal models have suggested
that angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers prevent the development of PAH by a
combination of mechanisms including vasodilation, reduction
of vascular smooth muscle proliferation, reduced collagen
deposition and inhibition of NF-ΚB activation [5,12,13]. Since
there are commonalities in the pathophysiology of PAH and
RP, particularly in the context of connective tissue disease,
inhibition of the renin–angiotensin system may prove effective
in RP. A pilot study of the angiotensin receptor blocker
losartan is encouraging. In a 12-week randomised trial of
losartan versus nifedipine in 25 patients with primary RP and
in 27 patients with SScl-associated RP, losartan was
significantly more effective than nifedipine in reducing both
the frequency and the severity of attacks [14].
PDE type V inhibitors such as sildenafil inhibit the
degradation of cGMP, which mediates the signalling of
several endogenous vasodilators [15]. Studies suggesting
efficacy of PDE type V inhibitors in animal models of PAH
have recently been supported by a small randomised,
placebo-controlled, double-blind crossover trial of sildenafil in
primary PAH. Twenty-two patients completed the study, and
treatment with sildenafil was associated with improvement in
symptoms, pulmonary haemodynamics and a 44% increase in
exercise time (P < 0.0001) [16]. Furthermore, a comparison
of the efficacy of bosentan versus sildenafil, when added to
conventional treatment for PAH, demonstrated that both
agents improved the haemodynamics and exercise capacity,
compared with baseline values, and that there was no
significant difference between the agents [17]. Similarly, use
of open-label sildenafil as adjunct therapy in PAH patients
receiving inhaled ilioprost appeared to improve symptoms,
haemodynamics and exercise capacity [18]. The apparent
efficacy of PDE inhibitors in PAH has made them attractive
candidates for treating RP. Case reports are encouraging but
controlled trials are required.
These approaches depart from the previously dominant
strategy for both PAH and RP, which was to achieve
symptomatic relief through vasodilatation [6]. Calcium
channel blockers are now recognised to have a limited role in
the management of PAH. They also appear to be of limited
benefit for RP in patients with SScl [19]. In contrast, the
prostanoids improve function and survival in PAH, and may
also be antiproliferative. In the healthy endothelium, prosta-
cyclin exerts vasodilatory and antithrombotic properties.
Epoprostenol, a synthetic prostacyclin, improves haemo-
dynamic and functional measures and improves survival in
patients with primary PAH, although the impact on survival is
less impressive in SScl. Continuous intravenous administration
of epoprostenol confers risks of infection and thrombosis.
More convenient routes of prostanoid delivery are also
showing promise (e.g. subcutaneous trepostinil, oral
beraprost and inhaled ilioprost).
RP is symptomatic of a generalised vasculopathy in SScl,
which eventually leads to a fibroproliferative arteriopathy.
PAH is one of many serious sequelae of this process. Current
evidence suggests that the symptom-led management
approach for SScl vasculopathy is outdated and that the
widespread use of calcium channel antagonists for RP is
probably inappropriate. It now appears preferable to use
agents for which there is some evidence of antiproliferative
activity. Since these approaches will probably be less
effective once fibrosis has occurred, it appears logical to
implement them in patients with early SScl; clinical trials are
required to test these proposals. However, there is room for
optimism that the cold hands and strained heart may prove
Figure 1
Dysfunction of cellular components of the arterial wall and of
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ushers of true disease-modifying therapy in this intractable
disease.
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